VolitionRx Limited Develops Groundbreaking Cancer Detection Tools
VolitionRx Limited (NYSE AMERICAN: VNRX) is at the forefront of advanced cancer diagnostics, having recently made headlines by securing its initial sale of the Nu.Q® Cancer assays. This key transaction marks an important milestone for the company as it partners with a leading cancer center in Europe, the Hospices Civils de Lyon. This sale not only signifies a crucial step in commercialization but also highlights the growing acceptance and implementation of innovative diagnostic tools in clinical settings.
First Sale to a Prominent Cancer Center
In a recent announcement, VolitionRx shared the exciting news of its first significant order from the Hospices Civils de Lyon. This prestigious facility in France is renowned for its dedication to advancing cancer treatment and is now set to utilize the Nu.Q® Cancer assays to enhance patient care via internal certification processes that precede the test’s integration into routine clinical practice.
Expert Voices on Nu.Q® Technology
Professor Léa Payen, a respected figure in Toxicology and Biochemistry at Claude Bernard University and the Hospices Civils de Lyon, expressed enthusiasm about the potential of Nu.Q® Cancer assays. She stated, “We are delighted to place this first order to complete the internal certification process ahead of introducing the test into routine clinical practice in our hospital network for cancer management.”
The collaboration between VolitionRx and the clinical team over several years underscores the importance of having reliable, scientific evidence backing the implementation of new diagnostic technologies. The findings indicate that measuring methylated nucleosome biomarker levels could provide crucial insights into Non-Small Cell Lung Cancer patients, aiding in personalized treatment strategies and improving survival rates.
Enhancing Decision-Making and Patient Monitoring
Dr. Andrew Retter, Chief Medical Officer at Volition, emphasized the implications of the Nu.Q® Cancer assays in clinical treatment decision-making. He noted, “This technology empowers clinicians to make more informed treatment decisions and offers new monitoring capabilities throughout the patient journey.” By contributing to clinical prognostication, the Nu.Q® Cancer assays facilitate a more tailored healthcare approach, ensuring that each patient benefits adequately from their treatment plans.
Significance of Lung Cancer Management
The role of Nu.Q® Cancer in managing lung cancer is especially crucial, as it provides healthcare professionals with an enhanced toolkit that improves how patients are diagnosed and treated. As described by Mr. Gael Forterre, Chief Commercial Officer of Volition, this sale is pivotal in their mission. He stated, “This is a major milestone for Volition in the commercialization of Nu.Q® in the human cancer field.”
Commitment to Advancing Cancer Diagnostics
The mission at VolitionRx is centered around pioneering research in epigenetics aimed at transforming cancer diagnostics and monitoring. The development of cost-effective and easy-to-use blood tests through their subsidiary companies is achieving profound implications for extending life and enhancing the quality of care for patients.
Volition’s research activities are driven by a multidisciplinary team based in Belgium, with additional offices in the U.S. and London. Their commitment to innovation reaffirms the company’s goal of offering healthcare professionals the necessary tools to make accurate diagnoses and monitor patient progress effectively.
Contact Information and Next Steps
For media inquiries, reach out to Louise Batchelor at Volition. For investor relations, Jeremy Feffer from LifeSci Advisors is available to answer questions regarding the company's progress and offerings.
Frequently Asked Questions
What are Nu.Q® Cancer assays?
Nu.Q® Cancer assays are innovative tests developed by VolitionRx to facilitate the detection and monitoring of certain cancer types, particularly lung cancer.
Who is using the Nu.Q® Cancer assays?
The first sale has been made to the Hospices Civils de Lyon, which will utilize these assays to enhance cancer patient management.
What is VolitionRx's main mission?
VolitionRx aims to advance the science of epigenetics in order to improve cancer diagnostics and treatment monitoring through innovative blood tests.
How do Nu.Q® assays impact treatment decisions?
The assays provide crucial biomarkers that help doctors make informed treatment decisions, enhancing personalized patient care.
Where is VolitionRx conducting its research?
VolitionRx conducts its research primarily in Belgium, with additional facilities in the United States and London focused on innovation in cancer diagnostics.
